Published • loading... • Updated
Mirum’s liver infection drug lowers virus levels in late-stage study
The drug was well tolerated, and 56% of patients on the lower dose and 45% on the higher dose improved at 24 weeks, Mirum said.
- On Monday, Mirum Pharmaceuticals announced its experimental drug Brelovitug met the primary goal of a late-stage study, successfully reducing hepatitis D virus levels in patients.
- Brelovitug targets chronic hepatitis delta, a liver infection affecting about 230,000 people in the US and Europe who are already infected with hepatitis B, a condition causing severe symptoms and potential liver damage.
- At 24 weeks, 56% of patients given 300 milligrams of Brelovitug and 45% given 900 milligrams showed reduced virus levels and normal liver enzyme levels, compared with 0% in the delayed-treatment group.
- RBC Capital Markets analyst Lisa Walter said Brelovitug has "a better benefit/risk profile," positioning it as best-in-class versus Gilead's Hepcludex, while Mirum reported the treatment was well tolerated across all dose groups.
- Mirum expects Brelovitug to generate peak sales of at least $1 billion and plans to submit a marketing application to the FDA in the first half of 2027 following full study results presentation.
Insights by Ground AI
11 Articles
11 Articles
Mirum's liver infection drug lowers virus levels in late-stage study
·London, United Kingdom
Read Full Article
Coverage Details
Total News Sources11
Leaning Left0Leaning Right3Center3Last UpdatedBias Distribution50% Center, 50% Right
Bias Distribution
- 50% of the sources are Center, 50% of the sources lean Right
50% Right
C 50%
R 50%
Factuality
To view factuality data please Upgrade to Premium
